Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

JAK inhibitors

- PMLiVE

GSK seeks EU approval for Trelegy in adult asthma patients

If approved would open up a large market for the triple therapy

- PMLiVE

Merck claims first-ever okay for Ebola vaccine, in Europe

Comes shortly after J&J filed its Ebola candidate with EMA

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

Actelion HQ Switzerland

Actelion gets EU go-ahead for Uptravi in PAH

Oral therapy predicted to become $1bn-plus product

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links